(TELA) Tela Bio - Ratings and Ratios

TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company specializing in soft-tissue reconstruction solutions designed to preserve and restore patient anatomy. The company offers a range of OviTex Reinforced Tissue Matrix products, including hernia repair and abdominal wall reconstruction solutions, as well as OviTex PRS for plastic and reconstructive surgery. Additionally, OviTex is available for laparoscopic and robotic-assisted procedures, utilizing sterile reinforced tissue matrices derived from ovine rumen with polypropylene fibers. The company distributes its products primarily through a direct sales force in the United States. Founded in 2012, TELA Bio is headquartered in Malvern, Pennsylvania.

The companys product portfolio addresses unmet clinical needs in hernia repair and reconstructive surgery, focusing on minimizing complications and improving surgical outcomes. Its OviTex line combines natural and synthetic materials to provide strength and facilitate tissue regeneration, making it suitable for a variety of surgical applications. TELA Bios direct sales model allows for targeted outreach to surgeons and healthcare providers, ensuring precise alignment with clinical demands.

Based on the provided data, here is a 3-month forecast:

Technical indicators suggest TELA shares may face near-term headwinds, as the stock price (2.34) is below its 20-day (2.63) and 50-day (2.72) moving averages, signaling potential weakness. The 200-day moving average (3.46) further indicates a downtrend. Average daily volume (143,688) and ATR (0.17) suggest manageable volatility. On the fundamental side, TELAs market cap (96.50M) and P/S ratio (1.41) align with its current growth stage, while the high P/B ratio (22.99) and negative P/E suggest elevated valuations relative to book value. The exceptionally high RoE (662.04) highlights strong profitability per equity dollar, though the lack of forward P/E indicates uncertainty about future earnings. Overall, TELA may experience short-term price pressure but could stabilize as clinical adoption of its products progresses.